SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
14.82 EUR
-0.04 (-0.27%)
Taking everything into account, 1SXP scores 5 out of 10 in our fundamental rating. 1SXP was compared to 21 industry peers in the Life Sciences Tools & Services industry. 1SXP has an excellent profitability rating, but there are some minor concerns on its financial health. 1SXP has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
In the past year 1SXP had a positive cash flow from operations.
Of the past 5 years 1SXP 4 years were profitable.
1SXP had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
1SXP's Return On Assets of 9.61% is amongst the best of the industry. 1SXP outperforms 90.91% of its industry peers.
1SXP has a Return On Equity of 17.02%. This is amongst the best in the industry. 1SXP outperforms 90.91% of its industry peers.
1SXP's Return On Invested Capital of 13.92% is amongst the best of the industry. 1SXP outperforms 90.91% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is significantly above the industry average of 9.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.02% | ||
| ROIC | 13.92% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
1SXP has a Profit Margin of 15.06%. This is amongst the best in the industry. 1SXP outperforms 86.36% of its industry peers.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
1SXP's Operating Margin of 19.46% is fine compared to the rest of the industry. 1SXP outperforms 77.27% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
The Gross Margin of 1SXP (33.73%) is worse than 63.64% of its industry peers.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.46% | ||
| PM (TTM) | 15.06% | ||
| GM | 33.73% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1SXP is still creating some value.
1SXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
1SXP has a debt to FCF ratio of 1.72. This is a very positive value and a sign of high solvency as it would only need 1.72 years to pay back of all of its debts.
1SXP has a better Debt to FCF ratio (1.72) than 100.00% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 95.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.72 | ||
| Altman-Z | N/A |
ROIC/WACC1.58
WACC8.81%
2.3 Liquidity
1SXP has a Current Ratio of 1.57. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP's Current ratio of 1.57 is fine compared to the rest of the industry. 1SXP outperforms 77.27% of its industry peers.
A Quick Ratio of 1.17 indicates that 1SXP should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.17, 1SXP is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -2.02% in the last year.
EPS 1Y (TTM)-2.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%4.44%
3.2 Future
Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.92% on average per year.
1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.94% yearly.
EPS Next Y18.66%
EPS Next 2Y16.45%
EPS Next 3Y15.84%
EPS Next 5Y13.92%
Revenue Next Year8.43%
Revenue Next 2Y9.34%
Revenue Next 3Y9.27%
Revenue Next 5Y7.94%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
1SXP is valuated correctly with a Price/Earnings ratio of 15.28.
Based on the Price/Earnings ratio, 1SXP is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.39, 1SXP is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 12.88, the valuation of 1SXP can be described as correct.
95.45% of the companies in the same industry are more expensive than 1SXP, based on the Price/Forward Earnings ratio.
1SXP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.84.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.28 | ||
| Fwd PE | 12.88 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 90.91% of the companies listed in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as 1SXP.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.39 | ||
| EV/EBITDA | 8.54 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1SXP has a very decent profitability rating, which may justify a higher PE ratio.
1SXP's earnings are expected to grow with 15.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y16.45%
EPS Next 3Y15.84%
5. Dividend
5.1 Amount
1SXP has a Yearly Dividend Yield of 1.21%.
In the last 3 months the price of 1SXP has falen by -31.55%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.54. 1SXP pays more dividend than 90.91% of the companies in the same industry.
Compared to the average S&P500 Dividend Yield of 1.87, 1SXP is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.21% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
1SXP pays out 16.40% of its income as dividend. This is a sustainable payout ratio.
DP16.4%
EPS Next 2Y16.45%
EPS Next 3Y15.84%
FRA:1SXP (12/19/2025, 7:00:00 PM)
14.82
-0.04 (-0.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners22.93%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.23B
Revenue(TTM)N/A
Net Income(TTM)146.90M
Analysts80
Price Target28.59 (92.91%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.21% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.4%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.61%
PT rev (3m)-4.36%
EPS NQ rev (1m)-4.49%
EPS NQ rev (3m)-4.49%
EPS NY rev (1m)-0.76%
EPS NY rev (3m)-2.08%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)-1.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.28 | ||
| Fwd PE | 12.88 | ||
| P/S | 2.29 | ||
| P/FCF | 44.39 | ||
| P/OCF | 10.96 | ||
| P/B | 2.59 | ||
| P/tB | 2.68 | ||
| EV/EBITDA | 8.54 |
EPS(TTM)0.97
EY6.55%
EPS(NY)1.15
Fwd EY7.77%
FCF(TTM)0.33
FCFY2.25%
OCF(TTM)1.35
OCFY9.12%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)0.82
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.02% | ||
| ROCE | 17.02% | ||
| ROIC | 13.92% | ||
| ROICexc | 14.45% | ||
| ROICexgc | 14.86% | ||
| OM | 19.46% | ||
| PM (TTM) | 15.06% | ||
| GM | 33.73% | ||
| FCFM | 5.15% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexgc growth 3Y-8.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.72 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 203.46% | ||
| Cap/Sales | 15.71% | ||
| Interest Coverage | 11.82 | ||
| Cash Conversion | 76.76% | ||
| Profit Quality | 34.23% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | N/A |
F-Score5
WACC8.81%
ROIC/WACC1.58
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y18.66%
EPS Next 2Y16.45%
EPS Next 3Y15.84%
EPS Next 5Y13.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%4.44%
Revenue Next Year8.43%
Revenue Next 2Y9.34%
Revenue Next 3Y9.27%
Revenue Next 5Y7.94%
EBIT growth 1Y12.08%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year46.87%
EBIT Next 3Y21.99%
EBIT Next 5Y18.79%
FCF growth 1Y-27.75%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y-5.4%
OCF growth 3Y19.45%
OCF growth 5YN/A
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 5 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 6 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 15.28 and the Price/Book (PB) ratio is 2.59.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 4 / 10 and the dividend payout ratio is 16.4%.